MoonLake Immunotherapeutics MLTX
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity lost 61 cents this year.
The 5-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue $B | ◌ | ◌ | ◌ | ◌ | ◌ |
| Operating income $B | −0.2 | −0.1 | −0.1 | −0.1 | −0.0 |
| EBITDA $B | −0.2 | −0.1 | −0.1 | −0.1 | ◌ |
| Income tax $B | 0.0 | 0.0 | 0.0 | 0.0 | ◌ |
| Net income $B | −0.2 | −0.1 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | −0.2 | −0.1 | −0.0 | −0.1 | ◌ |
| EPS, diluted $ | −3.53 | −1.89 | −0.73 | −1.70 | −0.31 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — |
| ROE % | −60.5 | −25.2 | −13.2 | — | — |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 4 of the 5 fiscal years we could check. 28 checks were skipped: the balance sheet is not tagged before 2021. 14 checks were skipped: EPS is not tagged before 2021.